ML
ITRM

McAdam LLC’s Iterum Therapeutics ITRM Stock Holding History

McAdam LLC’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800
Closed -$14K – 145
2020
Q2 		$14K Buy
+800
New +$31.7K ﹤0.01% 124

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

McAdam LLC's ITRM Position: Q3 2020 in Review

McAdam LLC sold out of Iterum Therapeutics (ITRM) in Q3 2020, closing a stake of 800 shares — an estimated $14K sold.

McAdam LLC first reported a position in ITRM in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 12 funds tracked by Wall St. Rank hold ITRM as of Q3 2020.

  • McAdam LLC reported no remaining Iterum Therapeutics position as of Q3 2020 after selling out during the quarter.
  • McAdam LLC sold 800 Iterum Therapeutics shares in Q3 2020, an estimated $14K.
  • McAdam LLC first reported a position in Iterum Therapeutics in Q2 2020 and held it in 1 quarter.
  • McAdam LLC's Iterum Therapeutics position peaked at $14K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2020.

Based on McAdam LLC's 13F filing for Q3 2020, filed 13 Nov 2020.